You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: May 5, 2024

Details for Patent: 9,700,537


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 9,700,537 protect, and when does it expire?

Patent 9,700,537 protects VASCEPA and is included in one NDA.

This patent has nine patent family members in six countries.

Summary for Patent: 9,700,537
Title:Composition for preventing the occurrence of cardiovascular event in multiple risk patient
Abstract: Disclosed is a composition which is useful for preventing the occurrence of a cardiovascular event, particularly a composition which is expected to show a prophylactic effect on a cardiovascular event occurring in a hypercholesterolemia patient despite providing the patient with a treatment with HMG-CoA RI or a cardiovascular event occurring in a multiple risk patient.
Inventor(s): Yokoyama; Mitsuhiro (Kobe, JP), Origasa; Hideki (Toyama, JP), Matsuzaki; Masunori (Ube, JP), Matsuzawa; Yuji (Takarzuka, JP), Saito; Yasushi (Chiba, JP)
Assignee: MOCHIDA PHARMACEUTICAL CO., LTD. (Tokyo, JP)
Application Number:15/431,958
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,700,537
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 9,700,537

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Amarin Pharms VASCEPA icosapent ethyl CAPSULE;ORAL 202057-001 Jul 26, 2012 AB RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE OCCURRENCE OF A CARDIOVASCULAR EVENT IN AN ADULT PATIENT WITH HYPERCHOLESTEROLEMIA ⤷  Try a Trial
Amarin Pharms VASCEPA icosapent ethyl CAPSULE;ORAL 202057-002 Feb 16, 2017 AB RX Yes No ⤷  Try a Trial ⤷  Try a Trial USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE OCCURRENCE OF A CARDIOVASCULAR EVENT IN AN ADULT PATIENT WITH HYPERCHOLESTEROLEMIA ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 9,700,537

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan2006-152740May 31, 2006

International Family Members for US Patent 9,700,537

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Canada 2653787 ⤷  Try a Trial
European Patent Office 2022495 ⤷  Try a Trial 122021000058 Germany ⤷  Try a Trial
European Patent Office 2022495 ⤷  Try a Trial 132021000000154 Italy ⤷  Try a Trial
European Patent Office 2022495 ⤷  Try a Trial C202130051 Spain ⤷  Try a Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.